126 related articles for article (PubMed ID: 1899042)
1. Expression of class I major histocompatibility complex antigens in Epstein-Barr virus-carrying lymphoblastoid cell lines and Burkitt lymphoma cells.
Jilg W; Voltz R; Markert-Hahn C; Mairhofer H; Münz I; Wolf H
Cancer Res; 1991 Jan; 51(1):27-32. PubMed ID: 1899042
[TBL] [Abstract][Full Text] [Related]
2. Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines.
Pokrovskaja K; Ehlin-Henriksson B; Bartkova J; Bartek J; Scuderi R; Szekely L; Wiman KG; Klein G
Cell Growth Differ; 1996 Dec; 7(12):1723-32. PubMed ID: 8959341
[TBL] [Abstract][Full Text] [Related]
3. Cell phenotype dependent expression of MHC class I antigens in Burkitt's lymphoma cell lines.
Masucci MG; Klein E
Semin Cancer Biol; 1991 Feb; 2(1):63-71. PubMed ID: 1655115
[TBL] [Abstract][Full Text] [Related]
4. Restoration of the LFA-3 adhesion pathway in Burkitt's lymphoma cells using an LFA-3 recombinant vaccinia virus: consequences for T cell recognition.
Griffin H; Rowe M; Murray R; Brooks J; Rickinson A
Eur J Immunol; 1992 Jul; 22(7):1741-8. PubMed ID: 1378014
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of nucleoskeleton- and cytoskeleton-associated proteins in Burkitt lymphoma-derived and Epstein-Barr virus-immortalized lymphoblastoid cell lines.
Szekely L; Pokrovskaja K; Klein G
Cell Growth Differ; 1997 May; 8(5):599-609. PubMed ID: 9149911
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease.
Dolcetti R; Frisan T; Sjöberg J; De Campos-Lima PO; Pisa P; De Re V; Gloghini A; Rizzo S; Masucci MG; Boiocchi M
Cancer Res; 1995 Aug; 55(16):3675-81. PubMed ID: 7627978
[TBL] [Abstract][Full Text] [Related]
7. Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma.
Rooney CM; Rickinson AB; Moss DJ; Lenoir GM; Epstein MA
IARC Sci Publ; 1985; (60):249-64. PubMed ID: 2998992
[TBL] [Abstract][Full Text] [Related]
8. Reduced signal transduction through glucocorticoid receptor in Burkitt's lymphoma cell lines.
Sinclair AJ; Jacquemin MG; Brooks L; Shanahan F; Brimmell M; Rowe M; Farrell PJ
Virology; 1994 Mar; 199(2):339-53. PubMed ID: 8122366
[TBL] [Abstract][Full Text] [Related]
9. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
10. Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection.
Callahan J; Pai S; Cotter M; Robertson ES
Virology; 1999 Sep; 262(1):18-30. PubMed ID: 10489337
[TBL] [Abstract][Full Text] [Related]
11. EBV-B cell interactions: immortalization, rescue from apoptosis, tumorigenicity (a short review).
Klein G
Acta Microbiol Immunol Hung; 1996; 43(2-3):97-105. PubMed ID: 8876725
[TBL] [Abstract][Full Text] [Related]
12. Viral and cellular factors influence the activity of the Epstein-Barr virus BCR2 and BWR1 promoters in cells of different phenotype.
Nilsson T; Sjöblom A; Masucci MG; Rymo L
Virology; 1993 Apr; 193(2):774-85. PubMed ID: 8384755
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.
Masucci MG; Torsteindottir S; Colombani J; Brautbar C; Klein E; Klein G
Proc Natl Acad Sci U S A; 1987 Jul; 84(13):4567-71. PubMed ID: 3037521
[TBL] [Abstract][Full Text] [Related]
14. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
Staege MS; Lee SP; Frisan T; Mautner J; Scholz S; Pajic A; Rickinson AB; Masucci MG; Polack A; Bornkamm GW
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4550-5. PubMed ID: 11917131
[TBL] [Abstract][Full Text] [Related]
15. Regulation of interleukin-1beta transcription by Epstein-Barr virus involves a number of latent proteins via their interaction with RBP.
Krauer KG; Belzer DK; Liaskou D; Buck M; Cross S; Honjo T; Sculley T
Virology; 1998 Dec; 252(2):418-30. PubMed ID: 9878621
[TBL] [Abstract][Full Text] [Related]
16. Selective induction of allostimulatory capacity after 5-azaC treatment of EBV carrying but not EBV negative Burkitt lymphoma cell lines.
Cuomo L; Trivedi P; de Campos-Lima PO; Zhang QJ; Ragnar E; Klein G; Masucci MG
Mol Immunol; 1993 Apr; 30(5):441-50. PubMed ID: 7681932
[TBL] [Abstract][Full Text] [Related]
17. T lymphocyte culture established by repeated stimulation with the autologous lymphoblastoid line. MHC class II restricted interactions with B blasts.
Torsteinsdottir S; Masucci MG; Szigeti R; Bishara A; Brautbar C; Klein G; Klein E
Mol Biol Med; 1984 Aug; 2(4):285-99. PubMed ID: 6443579
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
19. Expression of P2 receptors in human B cells and Epstein-Barr virus-transformed lymphoblastoid cell lines.
Lee DH; Park KS; Kong ID; Kim JW; Han BG
BMC Immunol; 2006 Sep; 7():22. PubMed ID: 16970829
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment with interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha up-regulates the expression of HLA class I determinants in Burkitt lymphoma lines.
Avila-Carino J; Torsteinsdottir S; Bejarano MT; Klein G; Klein E; Masucci MG
Cell Immunol; 1988 Dec; 117(2):303-11. PubMed ID: 2848629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
